

**To:** 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@astrazeneca.com>  
**Cc:** 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>;  
**From:** 5.1.2e <5.1.2e@minvws.nl>  
**Sent:** Tue 1/26/2021 10:23:07 PM  
**Subject:** RE: further to our call of 21/1  
**Received:** Tue 1/26/2021 10:23:15 PM

Dear 5.1.2e

Thank you for your email and the discussions on AZD7442.

We understand and we will try to accommodate as much as possible.

At this time I can confirm 5.1.1c 5.1.2e doses of AZD7442 are still available for advance purchase by the NLs. Early February should still be ok.

However, in full transparency, it's important to be aware that we cannot ensure availability after mid February.

We do need a signed advance purchase agreement (APA) contract for either 5.1.1c max doses to secure supply. The APA is only triggered following regulatory approval of AZD7442 as discussed. This provides security that the purchase is not made at risk.

As a way forward may I suggest that we work towards addressing any remaining questions and finalizing a potential advance purchase agreement contract latest by mid February to secure supply, if you chose to sign the agreement at that time?

Ad and I remain available if you have any questions.

Kind regards,

5.1.2e

AstraZeneca

M: +5.1.2e

5.1.2e <5.1.2e@astrazeneca.com>

PA:

5.1.2e

5.1.2e <5.1.2e@astrazeneca.com>

**From:** 5.1.2e <5.1.2e@minvws.nl>

**Sent:** vrijdag 22 januari 2021 11:17

**To:** 5.1.2e <5.1.2e@astrazeneca.com>; 5.1.2e <5.1.2e@astrazeneca.com>

**Cc:** 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>;

(5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>;

<5.1.2e@minvws.nl>

**Subject:** further to our call of 21/1

Dear 5.1.2e

Thank you again for yesterday's video call on a possible advance purchase agreement for your product AZD7442.

In the call you mentioned a deadline of 31/1/21 for a declaration of commitment from our side, in order for you to be able to secure the physical product for NL.

As we indicated yesterday we need more time to inform our decision-making process and therefore we request AZ to reconsider the deadline. In our view we need to await the availability of clinical data that are due in February to give a definite go on an agreement. This would facilitate a careful consideration on public needs and expenses. In December AZ indicated to strive to an agreement by February at the latest.

Therefore we request AZ to reconsider the indicated date. Would you please inform us on your response by Tuesday at the latest?

With best regards

5.1.2e

Ministerie van VWS

---

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at [www.astrazeneca.com](http://www.astrazeneca.com)